# Duane Boise Type: Person Source: GetYourBrief — https://getyourbrief.com/entity/duane-boise Canonical HTML page: https://getyourbrief.com/entity/duane-boise ## Timeline - **2026-08-17**: Post-Hearing Briefs Due — Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter. - **2026-08-16**: MMJ International Holdings issues legal warning — MMJ said that operational implementation of the administration's cannabis agenda does not equal legal finality and that its federal challenges could yield a stay, remand, vacatur, or targeted relief. - **2026-08-15**: CNBC reports cannabis as emerging midterm issue — A CNBC report highlighted marijuana policy as an emerging 2026 midterm issue, noting ballot measures in Massachusetts and Idaho and gubernatorial races in Kansas and Iowa. - **2026-07-16**: Senate Democrats reintroduce Cannabis Administration and Opportunity Act — 17 Senate Democrats reintroduced the CAOA, maintaining federal cannabis reform pressure while administrative actions proceed. - **2026-07-08**: Rescheduling Hearing Testimony — Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation. - **2026-07**: ALJ Hearing on Marijuana Rescheduling — A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence. - **2026-06-29**: Scheduled DEA hearing on rescheduling — A DEA administrative hearing is set to take place, which CEO Duane Boise calls less significant than the appellate court action. - **2026-06-19**: MMJ announces advancement of legal challenge — Company issues press release declaring that the D.C. Circuit challenge has advanced and that the operative legal event is the court review, not the upcoming DEA hearing. - **2026-06-18**: Statement of Issues filed — MMJIH files a Statement of Issues in the D.C. Circuit Court of Appeals seeking vacatur of the Final Order. - **2026-06**: DEA Excludes MMJ from Rescheduling Hearing — The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law. - **2026-04-22**: Acting Attorney General issues Final Order — Todd Blanche places marijuana into Schedule III of the Controlled Substances Act via a Final Order. - **2026-04**: Attorney General orders marijuana moved to Schedule III — The AG issues an order rescheduling state‑licensed medical marijuana and establishing a novel federal registration system for state marijuana businesses. - **2024**: Initial DEA hearing process begins — A hearing process on marijuana rescheduling begins under the Controlled Substances Act, later terminated by the government according to petitioners. - **2024**: DEA Scientific Data Review Published — Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use. - **2018-12**: MMJ files DEA bulk‑manufacturer application — MMJ International Holdings submits an application to manufacture active pharmaceutical ingredients for cannabinoid drugs, which remains pending nearly eight years later. ## Recent coverage (15 stories, network-wide) ### MMJ: AG Order 6754-2026 Faces Stay, Remand or Vacatur 2026-08-16 18:58:47 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2 For legal and regulatory professionals, MMJ's statement exposes the volatile gap between administrative implementation and judicial finality. The dispute could generate stay, remand, or vacatur rulings that determine whether operators can rely on current federal cannabis policies. Full story: https://getlegalbrief.com/story/mmj-federal-challenges-ag-order-6754-2026-legal-risk ### IRS 280E Relief and CMS Hemp Move Face Legal Uncertainty 2026-08-16 18:58:37 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2 Health systems and health IT vendors building around CMS's hemp-derived cannabinoid initiative are on contested regulatory ground. A successful federal challenge could stay or remand the program, changing compliance and reimbursement calculations. Full story: https://gethealthbrief.com/story/cms-hemp-280e-legal-uncertainty-health-systems ### Cannabis 280E Tax Relief Faces Clawback Risk Amid Litigation 2026-08-16 18:58:26 · Sector: finance · Sentiment: Negative · Impact: 6/10 · Sources: 2 Investors and lenders in cannabis and hemp face event risk from MMJ's federal challenges to the administration's accelerated policies. Current 280E tax relief and DEA registration activity may be reversed if courts intervene. Full story: https://getfinancebrief.com/story/cannabis-280e-tax-relief-clawback-litigation ### AG Order 6754-2026 Could Still Face Vacatur, MMJ Warns 2026-08-16 18:58:15 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 2 Biotech and pharma teams evaluating cannabinoid-derived drugs face unsettled federal scheduling and reimbursement policy. MMJ's litigation could alter DEA and CMS pathways through stay, remand, or vacatur. Full story: https://getbiobrief.com/story/dea-cannabis-rescheduling-6754-2026-biotech-risk ### DEA's 5-Part Medical-Use Test Under Fire as Marijuana Rescheduling Hearing Heads to August 17 Briefs 2026-08-10 03:18:11 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2 ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard. Full story: https://getlegalbrief.com/story/dea-marijuana-rescheduling-legal-tensions ### After $10M FDA Pursuit, MMJ Challenges AG’s Marijuana Rescheduling as Flawed 2026-07-30 20:03:11 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 4 A D.C. Circuit review of the Attorney General’s April 2026 order moving medical marijuana to Schedule III puts administrative law front and center. MMJ International Holdings argues the AG skipped required rulemaking and evidentiary hearings, threatening the integrity of the Controlled Substances Act’s scheduling process. Full story: https://getlegalbrief.com/story/ag-rescheduling-legal-challenge-mmj ### $10M at Risk: D.C. Circuit Could Overturn Cannabis Schedule III, Shaking Market 2026-07-30 20:02:47 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 4 Investors face renewed uncertainty as a federal court considers whether the Attorney General acted improperly in moving state medical marijuana to Schedule III. An adverse ruling could unwind tax and banking benefits that have underpinned bullish cannabis investment theses, potentially erasing billions in market capitalization. Full story: https://getfinancebrief.com/story/cannabis-stocks-rescheduling-court-risk ### DEA's Own Expert: Marijuana Fails 3 of 5 Medical Use Factors—Order at Risk 2026-07-27 07:23:59 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2 DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking. Full story: https://getlegalbrief.com/story/dea-expert-marijuana-fails-medical-use-test-legal-challenge ### APA Challenge: MMJ’s D.C. Circuit Appeal Tests Whether DEA Can Bypass Statutory Hearings 2026-07-27 04:21:36 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2 The MMJ International Holdings petition raises fundamental administrative law questions: can an agency issue a final rescheduling order before conducting the hearing required by the Controlled Substances Act? The D.C. Circuit’s answer will shape DEA’s authority over all future scheduling actions. Full story: https://getlegalbrief.com/story/apa-challenge-marijuana-rescheduling-dc-circuit-mmj ### DEA Rescheduling Hearing on June 29 Faces Pre-Emptive Legal Challenge—What It Means for Patients 2026-07-27 04:20:27 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2 MMJ International Holdings' appeal to the D.C. Circuit exposes a procedural flaw in the DEA's marijuana rescheduling that could delay patient access to new cannabinoid medicines and create confusion for healthcare providers trying to navigate the shifting regulatory landscape. Full story: https://gethealthbrief.com/story/marijuana-rescheduling-legal-challenge-patient-access-cannabinoid-medicines ### DEA Excluded MMJ, Only FDA-Pathway Developer with $10M in Research, from Rescheduling Hearing 2026-07-13 06:01:24 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2 MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule. Full story: https://getlegalbrief.com/story/dea-excludes-mmj-fda-cannabinoid-rescheduling-hearing ### MSO Stock Catalyst? $2.2B Annual Tax Release at Stake in Marijuana Rescheduling Case 2026-07-12 01:19:12 · Sector: finance · Sentiment: Positive · Impact: 9/10 · Sources: 1 Investors are watching the D.C. Circuit case closely as MMJ International Holdings claims marijuana rescheduling would deliver over $2 billion in annual tax savings to multi-state operators, potentially boosting profitability and stock prices. Full story: https://getfinancebrief.com/story/mso-tax-savings-rescheduling-case ### Cannabis Startups Could Pocket $2.2B in Tax Savings If Rescheduling Holds, Advocate Warns 2026-07-12 01:18:06 · Sector: startups · Sentiment: Positive · Impact: 9/10 · Sources: 1 MMJ International Holdings' latest filing reveals that up to $2.24 billion in annual 280E tax overpayments could be reversed, plus $1.6B in accrued unpaid taxes forgiven—a sum that would transform balance sheets for cash-strapped cannabis startups. Full story: https://getstartupbrief.com/story/cannabis-startups-280e-tax-windfall ### Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says 2026-07-12 01:17:30 · Sector: bio · Sentiment: Positive · Impact: 9/10 · Sources: 1 The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes. Full story: https://getbiobrief.com/story/cannabis-rescheduling-biotech-tax-savings ### Medical Cannabis Could See $2.2B Annual Tax Relief from Rescheduling, Challenger Claims 2026-07-12 01:16:54 · Sector: health · Sentiment: Positive · Impact: 9/10 · Sources: 1 MMJ International Holdings says moving cannabis to Schedule III would wipe out $2.24B in annual excess 280E taxes, unlocking capital for patient programs and medical research. The legal dispute spotlights the massive healthcare economic stakes of drug scheduling. Full story: https://gethealthbrief.com/story/medical-cannabis-tax-relief-rescheduling --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.